Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Regulatory Status AOD-9604 is supplied strictly for in vitro and preclinical research purposes
GLP-1s: Lower blood sugar Reduce appetiteso you eat less and feel fuller Promote healthy weight loss Improve metabolism Lower whole-body inflammationincluding that which affects your joints GLP-1s Target Both Metabolic and Inflammatory Pathways Recent research shows that GLP-1 medications can: Lower levels of inflammatory cytokines like TNF-alpha, IL-6, and IL-1 Restore a healthier gut microbiome and calm immune reactions Reduce fat-driven inflammationwhy losing just 510% of body weight improves autoimmune diseases Reverse insulin resistancea key link between metabolic and autoimmune disease Reduce oxidative stress, protecting organs and joint cartilage GLP-1s in RA, PsA, OA, and More: Evidence and Results Rheumatoid Arthritis Obesity increases RA risk and severity
Consider consuming a nutritious meal before the treatment to avoid an empty stomach
Top 20 Companies in Global Glucagon-Like Peptide-1 Agonists Market (20262035): Expert View By Spherical Insights RELEASE DATE: May 2026 Author: Spherical Insights According to a research report published by Spherical Insights & Consulting, The Global Glucagon-Like Peptide-1 Agonists Market size is projected to grow from USD 46.18 Billion in 2025 to USD 160.42 Billion by 2035, at a CAGR of 13.28% during the forecast period 20262035
US$ 22.66
US$ 28.27
US$ 26.28
US$ 20.42
US$ 23.85
US$ 27.65
US$ 27.23
US$ 23.19
US$ 22.60
US$ 24.91
